Venova Technologies Secures $2.23M Grant to Revolutionize Women’s Health with Innovative Hormone-Free Birth Control

Venova Technologies is excited to announce an important milestone in our journey towards revolutionizing women's health: we have successfully raised $2,230,000 in funding, primarily supported by the NIH. As a women-led startup, our mission focuses on the development of an innovative female birth control device that is highly effective, long-acting, and side-effect-free. Unlike traditional hormonal or copper-based methods, our solution is hormone-free and copper-free, offering a reduced side effect profile that meets a significant global unmet need in women's health. This infusion of capital will accelerate our efforts to further refine our technology, conduct rigorous clinical trials, and expand strategic partnerships across the healthcare ecosystem. The financial support not only validates our pioneering approach but also propels us into the next phase of research and development. Our technology has already garnered notable recognition through various awards, including the First Place Women Who Empower Award in 2021, the First Place Life Sciences Eddie Award in 2023, and multiple accolades in 2024, such as the FemHealth Insights First in FemTech Award and the Women's Health Innovation Summit Showcase Award. Additionally, our participation in leading accelerator and fellowship programs—ranging from the NSF I-Corps Program in 2019 to our upcoming engagement in The Science Center Capital Readiness Program in 2025—demonstrates our commitment to excellence and innovation. This funding milestone is not just a financial achievement; it marks a turning point in advancing a new era of female contraceptive technology. We are energized by the trust placed in our vision and are dedicated to ensuring that our breakthrough device reaches women everywhere, offering a safer, more effective alternative in personal healthcare options.